Login to Your Account



Valeant Gains Clearance For Parkinson's Adjunct, Zelapar

By Jennifer Boggs


Friday, June 16, 2006
Two years after being labeled approvable by the FDA, Zelapar, a version of the Parkinson's disease drug selegiline designed using a fast-dissolving oral delivery system, finally was given the go-ahead to launch. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription